您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > JAK-2/3-IN-3
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
JAK-2/3-IN-3
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
JAK-2/3-IN-3图片
包装与价格:
包装价格(元)
100mg电议
250mg电议
500mg电议

产品介绍
JAK-2/3-IN-3 (化合物 ST4j) 是一种强效的JAK2/3抑制剂,其对JAK2JAK3IC50值分别为 13.00 和 14.86 nM。JAK-2/3-IN-3 以剂量和时间依赖的方式抑制JAK2的自磷酸化并诱导细胞凋亡。JAK-2/3-IN-3 可用于淋巴衍生疾病和白血病的研究。
生物活性

JAK-2-/3-IN-3 (compound ST4j) is a potentJAK2/3inhibitor withIC50s of 13.00 and 14.86 nM forJAK2andJAK3, respectively. JAK-2-/3-IN-3 inhibits autophosphorylation ofJAK2and inducesapoptosisin a dose- and time-dependent manner. JAK-2-/3-IN-3 can be used in studies of lymph derived diseases and leukemia[1].

IC50& Target[1]

JAK2

13.00 nM (IC50)

JAK3

14.86 nM (IC50)

体外研究
(In Vitro)

JAK-2/3-IN-3 (0-100 μM; 72 h) specifically inhibits human erythroleukemia cells with low toxicity to the normal cells[1].
JAK-2/3-IN-3 inhibits human erythroleukemia TF1 cell growth via the JAK2/STAT5 signaling pathway[1].
JAK-2/3-IN-3 (15.53 μM; 24, 48, 72 h) induces cytotoxicity via apoptosis in a time-dependent manner in TF1 cells[1].
JAK-2/3-IN-3 (IC25, IC50, IC75; 24 h) induces cytotoxicity via apoptosis in a dose-dependent manner in TF1 cells[1].

Apoptosis Analysis[1]

Cell Line:TF1 cells
Concentration:15.53 μM
Incubation Time:24, 48, 72 h
Result:Increased cells apoptotic by ~20%, ~40% and ~70%, after 24-, 48- and 72-h incubations, respectively.
Increased cells apoptotic by ~15%, 20%, and 30% with concentration of IC25, IC50and IC75, respectively.

Cell Cytotoxicity Assay[1]

Cell Line:TF1, HEL, Vero and HepG2 cells
Concentration:0-100 μM
Incubation Time:72 h
Result:Inhibited growth of TF1 and HEL cells, with IC50s of 15.53 and 17.90 μM.
Showed low toxic to normal Vero cells and HepG2 cells (IC50of >100 μM in Vero cells and of >50 μM in HepG2 cells).
分子量

325.15

Formula

C13H10Cl2N4O2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.